BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 4
• 5
• 6
• 7
• 8
• 11
• 12
• 13
• 14
• 15
• 18
• 19
• 20
• 21
• 22
• 23
• 25
• 26
• 27
• 28
• 29

• 

  Government

  Trump Picks RFK Jr. to Lead HHS

  Trump’s HHS pick, Robert F. Kennedy Jr., is an anti-vaccine campaigner who has previously said that he plans to gut the FDA on allegations of corruption and reduce the NIH’s headcount.

  November 15, 2024

   · 

  3 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Eyenovia Shares Plummet 70% After It Drops Lead Program

  Eyenovia’s stock craters to its lowest point in its six-year lifespan as a public company following the biotech’s termination of its lead program in pediatric progressive myopia due to lack of efficacy.

  November 15, 2024

   · 

  2 min read

   · 

  Heather McKenzie
• 

  Earnings

  Bluebird Faces Cash Gap With Breakeven Point in Sight

  Bluebird has just two quarters until it’s out of cash. Executives are looking for financing to extend that runway to a projected breakeven point before the end of 2025, with analysts worried they won’t make it.

  November 15, 2024

   · 

  4 min read

   · 

  Annalee Armstrong
• 

  Editorial

  Pharma’s Q3 Was a Rollercoaster Ride. Let’s Do It Again Next Quarter

  Big Pharma had plenty of drama to keep journalists busy this quarter, which painted an accurate portrait of the wild and wonderful world of biopharma.

  November 15, 2024

   · 

  3 min read

   · 

  Annalee Armstrong
• 

  Layoffs

  Gilead and Kite Are Cutting Employees, Closing Seattle, Philadelphia Sites

  Gilead’s layoffs include 72 employees at its Seattle location, which will close. Kite will shut down its Philadelphia facility. The layoffs are attributed to aligning resources with long-term strategic goals.

  November 15, 2024

   · 

  2 min read

   · 

  Angela Gabriel
• 

  Legal

  Celgene Shareholders Hit BMS with Fresh Lawsuit for Allegedly Dodging CVR Payments

  BMS has so far been on a winning streak in the contingent value right cases, which allege that the pharma intentionally delayed regulatory activities for Breyanzi in order to avoid a $6.4 billion payout to Celgene shareholders.

  November 15, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  PharmaDrug Announces Issuance of Debenture Units

  November 15, 2024

   · 

  5 min read
• Press Releases

  Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B

  November 15, 2024

   · 

  13 min read
• Press Releases

  Justera Health Announces Management Change

  November 15, 2024

   · 

  5 min read
• Press Releases

  Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer

  November 15, 2024

   · 

  19 min read